Trinity Biotech notes Perceptive Advisors' indication of potential debt-to-equity conversion ($1.00, 0.00)
Trinity Biotech announces in-country regulatory approval for offshored and outsourced manufacturing of its TrinScreen HIV rapid test ($1.37, 0.00)
Trinity Biotech receives NY state regulatory approval to begin FDA-cleared PreClara preeclampsia testing service ($1.01, 0.00)
Trinity Biotech announces clinical trial results for redesigned CGM sensor; confirms accurate glucose readings across full 15-day wear period ($0.83, 0.00)
Trinity Biotech provides business update; reports Q1 highlights, now expects to be adjusted EBITDA-positive starting in Q3 2025 and into the foreseeable future ($0.65, 0.00)
Trinity Biotech secures WHO approval for offshored and outsourced manufacturing of its flagship rapid HIV test ($0.55, 0.00)
Trinity Biotech reports Q4 EPS ($1.28) vs year-ago $0.72 ($0.84, 0.00)
Trinity Biotech appoints Barclays as financial advisor to support its ongoing strategic realignment ($0.68, 0.00)
Trinity Biotech obtains additional $4M in debt financing from primary lender Perceptive Advisors ($0.75, 0.00)
Trinity announces new findings from its latest pre-pivotal trial for its next-generation continuous glucose monitoring (CGM) system ($0.86, 0.00)
Powered by FactSet Research Systems Inc.